announces that it has received C$ 2.4 million in new equity capital from the partial exercise of expiring share purchase warrants.

Microbix and American Proficiency Institute (API), a groundbreaking supplier of proficiency testing (“PT”) to over 20,000 clinical laboratories, announce the start of a pilot PT program to ensure that molecular diagnostic (“MDx”) assays can detect the emerging H5N1 strain of the Influenza A virus (“H5N1 Flu”).

announces its intentions to broaden its platform capabilities to enable production of a wider range of test ingredients (“Antigens”) by using recombinant production technologies.

reports results for its fiscal year and fourth quarter ended September 30, 2024 (“2024” and “Q4”) with record revenues, reflective of ongoing progress to increase sales from its diagnostic-test related ingredients and devices businesses and that resulted in material net income for 2024 and Q4.

announces that it expects to file the financial statements and management disclosure and analysis for its fourth quarter of fiscal 2024 ended September 30, 2024 (“Q4 2024”) prior to the start of trading on December 19, 2024. At 11:00 AM ET on that day, Microbix intends to hold a webinar discussion of Q4 2024 results with its CEO, CFO, and COO.